









市场行情
/
股票
/
nasdaq-plx
/

Protalix Biotherapeutics Inc

PLX

1.780USD

+0.050+2.89%

交易中（美东）报价延迟15分钟

143.01M总市值

23.75市盈率 TTM



Protalix Biotherapeutics Inc

1.780

+0.050+2.89%

概览公司财务分析

概览

公司

财务

分析

关于 Protalix Biotherapeutics Inc 公司

Protalix BioTherapeutics, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. In addition, the Company is developing PEGylated uricase, or PRX-115, for the treatment of uncontrolled gout, Long Acting (LA) DNase I, or PRX-119, for the treatment of NETs-related diseases, and other technologies and preclinical assets. Its ProCellEx platform is being used to manufacture both of its approved and marketed products as well as PRX-115 and PRX-119. PRX-115, a plant cell-expressed recombinant PEGylated Uricase (urate oxidase) - a chemically modified enzyme to treat uncontrolled gout. PRX-119 is a plant cell-expressed PEGylated recombinant human DNase I product candidate. Its product includes Elelyso and Elfabrio. Elelyso is an enzyme replacement therapy (ERT) for the treatment of patients with Gaucher disease.

Protalix Biotherapeutics Inc简介



公司代码PLX

公司名称Protalix Biotherapeutics Inc

上市日期Sep 06, 2010

CEOBashan (Dror)

员工数量207

证券类型Ordinary Share

年结日Sep 06

公司地址2 University Plaza

城市HACKENSACK

上市交易所NASDAQ OMX – NASDAQ Basic Amex

国家United States of America

邮编07601

电话12016969345

网址https://protalix.com/

公司代码PLX

上市日期Sep 06, 2010

CEOBashan (Dror)

Protalix Biotherapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Dror Bashan

President, Chief Executive Officer, Director

2.28M

Dr. Aharon Schwartz, Ph.D.

Independent Director

303.00K

+74.14%

Mr. Yaron Naos

Senior Vice President - Operations

207.30K

Ms. Gwen A. Melincoff

Independent Director

40.00

Dr. Pol F. Boudes, M.D.

Independent Director

40.00

Mr. Mike Moyer

Investor Relations

Mr. Amos Bar Shalev

Independent Director

Dr. Shmuel (Muli) Ben-Zvi, Ph.D.

Independent Director

Dr. Eliot Richard Forster, Ph.D.

Independent Chairman of the Board

Mr. Gilad Mamlok

Chief Financial Officer, Senior Vice President

名称

名称/职务

职务

持股

持股变动

Mr. Dror Bashan

President, Chief Executive Officer, Director

2.28M

Dr. Aharon Schwartz, Ph.D.

Independent Director

303.00K

+74.14%

Mr. Yaron Naos

Senior Vice President - Operations

207.30K

Ms. Gwen A. Melincoff

Independent Director

40.00

Dr. Pol F. Boudes, M.D.

Independent Director

40.00

Mr. Mike Moyer

Investor Relations

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月16日周日

持股股东

股东类型

持股股东

占比

HIR Investments Ltd

5.86%

BlackRock Institutional Trust Company, N.A.

3.97%

Opaleye Management Inc.

3.21%

Bashan (Dror)

2.84%

Renaissance Technologies LLC

1.64%

其他

82.49%

持股股东

占比

HIR Investments Ltd

5.86%

BlackRock Institutional Trust Company, N.A.

3.97%

Opaleye Management Inc.

3.21%

Bashan (Dror)

2.84%

Renaissance Technologies LLC

1.64%

其他

82.49%

股东类型

持股股东

占比

Investment Advisor

8.57%

Corporation

5.86%

Hedge Fund

4.97%

Individual Investor

4.29%

Investment Advisor/Hedge Fund

3.55%

Research Firm

0.18%

Venture Capital

0.11%

Bank and Trust

0.09%

Pension Fund

0.06%

其他

72.32%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

176

12.24M

15.35%

+846.09K

2025Q2

183

18.79M

23.60%

+3.26M

2025Q1

182

19.45M

25.30%

+4.26M

2024Q4

169

15.65M

21.26%

-1.03M

2024Q3

162

14.11M

19.17%

-5.41M

2024Q2

163

16.36M

22.25%

-4.44M

2024Q1

143

16.45M

23.43%

-4.40M

2023Q4

145

17.20M

24.67%

-3.21M

2023Q3

142

16.45M

24.08%

-6.46M

2023Q2

132

16.38M

24.76%

-4.13M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

HIR Investments Ltd

4.71M

5.91%

Apr 30, 2025

BlackRock Institutional Trust Company, N.A.

3.00M

3.77%

+2.84M

+1741.73%

Jun 30, 2025

Bashan (Dror)

2.28M

2.86%

Apr 30, 2025

Renaissance Technologies LLC

1.62M

2.03%

+426.05K

+35.83%

Jun 30, 2025

Geode Capital Management, L.L.C.

826.33K

1.04%

+826.33K

Jun 30, 2025

Rubin (Eyal)

660.91K

0.83%

+90.91K

+15.95%

Apr 30, 2025

Northern Trust Global Investments Limited

689.88K

0.87%

+6.58K

+0.96%

Jun 30, 2025

Stratos Wealth Partners, Ltd.

350.00K

0.44%

+3.60K

+1.04%

Jun 30, 2025

State Street Investment Management (US)

444.24K

0.56%

+148.14K

+50.03%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.03%

Franklin US Small Cap Multifactor Index ETF

0.01%

iShares Russell 2000 Growth ETF

0.01%

Proshares Ultra Russell 2000

0.01%

Global X Russell 2000 ETF

0.01%

Invesco Russell 2000 Dynamic Multifactor ETF

0.01%

DFA Dimensional US Sustainability Core 1 ETF

ProShares UltraPro Russell2000

Goldman Sachs ActiveBeta US Small Cap Equity ETF

Avantis International Small Cap Equity ETF

iShares Micro-Cap ETF

占比0.03%

Franklin US Small Cap Multifactor Index ETF

占比0.01%

iShares Russell 2000 Growth ETF

占比0.01%

Proshares Ultra Russell 2000

占比0.01%

Global X Russell 2000 ETF

占比0.01%

Invesco Russell 2000 Dynamic Multifactor ETF

占比0.01%

DFA Dimensional US Sustainability Core 1 ETF

占比0%

ProShares UltraPro Russell2000

占比0%

Goldman Sachs ActiveBeta US Small Cap Equity ETF

占比0%

Avantis International Small Cap Equity ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Protalix Biotherapeutics Inc的前五大股东是谁？



Protalix Biotherapeutics Inc 的前五大股东如下：
HIR Investments Ltd持有股份：4.71M，占总股份比例：5.91%。
BlackRock Institutional Trust Company, N.A.持有股份：3.00M，占总股份比例：3.77%。
Bashan (Dror)持有股份：2.28M，占总股份比例：2.86%。
Renaissance Technologies LLC持有股份：1.62M，占总股份比例：2.03%。
Geode Capital Management, L.L.C.持有股份：826.33K，占总股份比例：1.04%。